{"name":"AZTherapies, Inc.","slug":"aztherapies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALZT-OP1a","genericName":"ALZT-OP1a","slug":"alzt-op1a","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"},{"name":"ALZT-OP1b","genericName":"ALZT-OP1b","slug":"alzt-op1b","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"}]}],"pipeline":[{"name":"ALZT-OP1a","genericName":"ALZT-OP1a","slug":"alzt-op1a","phase":"phase_3","mechanism":"ALZT-OP1a is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""},{"name":"ALZT-OP1b","genericName":"ALZT-OP1b","slug":"alzt-op1b","phase":"phase_3","mechanism":"ALZT-OP1b is a small molecule that modulates tau pathology and neuroinflammation to slow cognitive decline in Alzheimer's disease.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQTXhpeXVRaExidUFhVmlYNlNyd3NwUFFYVEQzVG1mVldKdXVTXzNVUDZLVVRQU0QtMG1rZFF0UzZnbEhTQnNmbmhPNW8yOGg5RnRSeXpDZEpHckpQYnpxcnMxcG8zMl9wQTEyNGVNbHNtS20wNDJnNVJITWlKdjlVMXpwSDJqVjFBVFRoWkgxakVTZ0x0eHVVck1fYw?oc=5","date":"2026-04-03","type":"pipeline","source":"Tracxn","summary":"DRADS Capital - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn","headline":"DRADS Capital - 2026 Investor Profile, Portfolio, Team & Investment Trends","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRzFPVXJGUDZUaXl4Y0JqSHMwMVctcTdBaHZaV3BfTUVRbXlXT0hfSG9tLXcyRDBUSHphdHhZXzFOTks3VVZuTkdReVUyVDNWY191TUFwWWt0ejUxUTh6YXMxV3VqbV9Zazl2NUFZSWVYR1RaVkI3RWU1R3cxUFZ3UWc2UmdxN2tHM3g3WUtCVkhEUQ?oc=5","date":"2020-10-01","type":"pipeline","source":"Fierce Biotech","summary":"Ex-Ipsen boss de Garidel takes the helm at AZTherapies - Fierce Biotech","headline":"Ex-Ipsen boss de Garidel takes the helm at AZTherapies","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}